Back to Journals » Breast Cancer: Targets and Therapy » Volume 3

Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update

Authors Schneider R, Barakat A, Pippen JE, Osborne C

Published 4 October 2011 Volume 2011:3 Pages 113—125


Review by Single anonymous peer review

Peer reviewer comments 6

Reva Schneider1, Ayman Barakat1, John Pippen1,2,3, Cynthia Osborne1,2,3
1Medical Oncology, Baylor-Sammons Cancer Center, 2Texas Oncology PA, 3US Oncology, Dallas, TX, USA

Abstract: Estrogen and its metabolites play a significant role in the proliferation of hormone receptor-positive breast cancer. In postmenopausal women, aromatase inhibitors can significantly reduce estrogen levels by blocking enzyme-mediated estrogen synthesis within tissues. Third-generation aromatase inhibitors have now surpassed tamoxifen as first-line therapy for postmenopausal women with metastatic, hormone receptor-positive, breast cancer, showing improved response rates and time to progression. Aromatase inhibitors have shown incremental improvements in disease-free survival, lower local recurrence rates, lower metastatic recurrence rates, and a lower incidence of contralateral breast cancer over tamoxifen when used in the adjuvant setting. Aromatase inhibitors are recommended to be used as adjuvant therapy within the first 5 years of hormonal therapy and may be used either upfront for 5 years or sequenced with tamoxifen. No superiority of one aromatase inhibitor over another has yet been shown. The side effect profiles of aromatase inhibitors have some key differences compared with tamoxifen. These differences may influence treatment choices as well as impact compliance.

Keywords: aromatase inhibitor, breast cancer, postmenopausal, hormonal therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]